Press Releases
AIE Renews Contract with Hologic for Mammography Workstation Features
October 1, 2017 (Providence, RI) – Advanced Image Enhancement (AIE), a provider of image enhancement tools for the medical imaging industry, today announced that its contract with Hologic will be renewed for cutting-edge image enhancement technology for digital mammography in breast cancer screening and diagnosis. AIE’s proprietary image enhancement software leverages signal processing technology originally developed from Navy research to locate undersea mines. In an expanded application, this technology enables physicians to extract more information from medical images. In a prior clinical study, researchers from Massachusetts General Hospital, Brigham and Women’s Hospital, Newton-Wellesley Hospital and Faulkner Hospital concluded that the AIE enhancement software provided a significant advantage for improving clarity of abnormalities, especially in dense breast tissue, and increased radiologists' confidence in determining their case management conclusions. AIE received clearance from the FDA in September, 2006, to market the technology.
“We are excited to continue our valued relationship with Hologic for the screening and diagnosis of breast cancer,” said Michael Duarte, CEO and founder of AIE. “As a complement to Hologic’s SecurView workstations, our software will continue to provide radiologists with the ability to enhance suspicious regions of interest in mammograms with greater image quality and detail. This is particularly important in cases where dense breast tissue is involved, because it presents the greatest challenges.”
AIE and eRAD Enter into Licensing Agreement
PROVIDENCE, RI/GREENVILLE, SC (August 2, 2013) -- Advanced Image Enhancement, Inc. (AIE) a provider of image enhancement tools for the medical imaging industry, announced today it has entered into an agreement with eRAD, Inc., a division of RadNet, Inc. (NASDAQ: RDNT), allowing eRAD to integrate the AIE image enhancement toolkit for mammography as an advanced image processing option to the eRAD PACS viewer (for mammography).
“Our agreement with eRAD serves as further validation that AIE image enhancement tools can be overlaid onto existing technology platforms allowing for greater specificity for reviewing mammography images,” stated Michael Duarte, CEO/Founder, AIE. “eRAD’s expansive network of clinical users throughout the U.S. provides an opportunity to leverage AIE’s imaging tools within the nation’s radiology community.”
AIE’s proprietary image enhancement software leverages signal processing technology originally developed from Navy research to locate undersea mines. In an expanded application, this technology enables physicians to extract more information from medical images. In a clinical study, researchers from Massachusetts General Hospital, Brigham and Women’s Hospital, Newton-Wellesley Hospital and Faulkner Hospital concluded that the AIE enhancement software provided a significant advantage for improving clarity of abnormalities in dense breast tissue and increased radiologists' confidence in determining their case management conclusions. AIE received clearance from the FDA in September, 2006, to market the technology.
“Providing technological advances that help physicians serve their patients is a priority at eRAD,” said Ranjan Jayanathan, eRAD’s General Manager. “AIE’s technology integrates well with eRAD‘s workstations, allowing our users the ability to screen and diagnose patient’s mammograms with the highest degree of proficiency.”
To date, thousands of physicians across the United States and Worldwide have tested and used AIE’s technology platform. According to Arnold Honick, M.D., Medical Director, Sutter North Bay Women’s Health and Breast Center, “For microcalcification evaluation, AIE Enhancement improves the morphology evaluation and best allows detection of the distribution and extent of microcalcifications. This allows detection of subtle microcalcifications and will improve localization procedures for definitive excision if the calcifications are found to be high risk.”